Anavex Life Sciences Corp (AVXL)

[boi568]

Between the low n and the high probability of outside funding, along with a lower regulatory bar for approval, each of these rare disease trials provide a lot of bang for the buck. And they are offer an inexpensive MOA demonstration.

Missling is being very strategic in how he is attacking the summit of this very steep and previously unscaled CNS mountain, both scientically and financially. He is not racing toward an easier base camp destination.